Loading...

RLMD RELMADA THERAPEUTICS INC Management Changes 8-K Filing

RLMD

RLMD

RELMADA THERAPEUTICS INC

(RLMD)

2025 8-K

Corporate Update

Funding Announcement

Management Changes

Corporate Update

Stock Offering Announcement

FDA Feedback Summary

Corporate Update

Compliance Update

Shareholder Update

Stock Purchase Alert

Financial Statements

Transfer of Listing

Divestment of Assets

Product Expansion

Financial Results

License Agreement

Asset Purchase Agreement

Nasdaq Compliance Notice

Management Changes

Study Discontinuation

Annual Meeting of Stockholders

Financial Results

Departure of Directors or C...

Departure of Directors

Earnings Reports

Annual Meeting Approval

Earnings Reports

Earnings Reports

Regulation FD Disclosure

Appointment of Director

Appointment, Presentation U...

Advisory Agreement with Pau...

External Links:

On December 12, 2025, Relmada Therapeutics, Inc. announced adjustments to employment agreements for its executive team effective January 1, 2026. Salaries will increase for CEO Sergio Traversa to $827,176, COO Paul Kelly to $524,790, CFO Maged Shenouda to $586,940, and Controller Charles Ence to $576,440.

AI Assistant

RELMADA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.